ArticleBMJ open2022

Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a descriptive cohort study assessing trends in patient characteristics in Switzerland.

Theresa Burkard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.